研究单位：[1]Hutchison Medipharma Limited[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[3]The Second Hospital of Anhui Medical University Hefei,Anhui,China,230601[4]Beijing Friendship Hospital,Capital Medical University Beijing,Beijing,China,100050[5]""Beijing Cancer Hospital Beijing,Beijing,China,100142""[6]Peking University Third Hospital Beijing,Beijing,China,100191[7]Chongqing University Cancer Hospital Chongqing,Chongqing,China,400030[8]Fujian Cancer Hospital Fuzhou,Fujian,China,350014[9]The First Affiliated Hospital of Xiamen University Xiamen,Fujian,China,361001[10]Sun Yat-sen University Cancer Center Guangzhou,Guangdong,China,510060
研究目的：
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)
